Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 9, 2024Journal of the American Heart AssociationOpen Access

Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study

View Full Paper
Ask AI
Bookmark
Share

Authors

HCHao‐Chih ChangYCYun‐Yu ChenTKTzu‐Ting Kuo

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Chang et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcafb6db643587676a69https://doi.org/10.1161/jaha.123.032397
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes2017 · 7,910 citations
  2. 2Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks2019 · 578 citations
  3. 3Dapagliflozin in Patients with Chronic Kidney Disease2020 · 5,532 citations
  4. 4Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment2020 · 284 citations
  5. 5Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors Versus Metformin2022 · 42 citations